Franz Worek

Prof. Franz Worek

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in Analytical Biochemistry
Verified
Journal Article
Closed access
PEPeter Eyer
Peter Eyer
FWFranz Worek
Franz Worek
DKDaniela Kiderlen
Daniela Kiderlen
Goran ŠinkoGoran Šinko
Goran Šinko
ASAnita Stuglin
Anita Stuglin
ERElsa Reiner
Elsa Reiner

1 December 2004 in Biochemical Pharmacology
Verified
Journal Article
Closed access
FWFranz Worek
Franz Worek
HTHorst Thiermann
Horst Thiermann
LSLadislaus Szinicz
Ladislaus Szinicz
PEPeter Eyer
Peter Eyer

1 October 2005 in The Lancet
Verified
Journal Article
Closed access
MEMichael Eddleston
Michael Eddleston
PEPeter Eyer
Peter Eyer
FWFranz Worek
Franz Worek
FMFahim Mohamed
Fahim Mohamed
LSLalith Senarathna
Lalith Senarathna
NBNick A Buckley
Nick A Buckley

1 March 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SWSylvia Wagner
Sylvia Wagner
AZAnja Zensi
Anja Zensi
SWSascha L. Wien
Sascha L. Wien
STSabrina E. Tschickardt
Sabrina E. Tschickardt
WMWladislaw Maier
Wladislaw Maier
HBHagen von Briesen
Hagen von Briesen
The blood-brain barrier (BBB) represents an insurmountable obstacle for most drugs thus obstructing an effective treatment of many brain diseases. One solution for overcoming this barrier is a transport by binding of these drugs to surface-modified nanoparticles. Especially apolipoprotein E (ApoE) appears to play a major role in the nanoparticle-mediated drug transport across the BBB. However, at present the underlying mechanism is incompletely understood. In this study, the uptake of the ApoE-modified nanoparticles into the brain capillary endothelial cells was investigated to differentiate between active and passive uptake mechanism by flow cytometry and confocal laser scanning microscopy. Furthermore, different in vitro co-incubation experiments were performed with competing ligands of the respective receptor. This study confirms an active endocytotic uptake mechanism and shows the involvement of low density lipoprotein receptor family members, notably the low density lipoprotein receptor related protein, on the uptake of the ApoE-modified nanoparticles into the brain capillary endothelial cells. This knowledge of the uptake mechanism of ApoE-modified nanoparticles enables future developments to rationally create very specific and effective carriers to overcome the blood-brain barrier.

6 June 2020 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
FWFranz Worek
Franz Worek
HTHorst Thiermann
Horst Thiermann
TWTimo Wille
Timo Wille
Organophosphorus (OP) pesticides and nerve agents still pose a threat to the population. Treatment of OP poisoning is an ongoing challenge and burden for medical services. Standard drug treatment consists of atropine and an oxime as reactivator of OP-inhibited acetylcholinesterase and is virtually unchanged since more than six decades. Established oximes, i.e. pralidoxime, obidoxime, TMB-4, HI-6 and MMB-4, are of insufficient effectiveness in some poisonings and often cover only a limited spectrum of the different nerve agents and pesticides. Moreover, the value of oximes in human OP pesticide poisoning is still disputed. Long-lasting research efforts resulted in the preparation of countless experimental oximes, and more recently non-oxime reactivators, intended to replace or supplement the established and licensed oximes. The progress of this development is slow and none of the novel compounds appears to be suitable for transfer into advanced development or into clinical use. This situation calls for a critical analysis of the value of oximes as mainstay of treatment as well as the potential and limitations of established and novel reactivators. Requirements for a straightforward identification of superior reactivators and their development to licensed drugs need to be addressed as well as options for interim solutions as a chance to improve the therapy of OP poisoning in a foreseeable time frame.

1 November 2016 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
FWFranz Worek
Franz Worek
HTHorst Thiermann
Horst Thiermann
TWTimo Wille
Timo Wille